Stockscreener 앱 받기
0.803
0.90%
-0.0073
시장 영업 전:
.80
-0.003
-0.37%
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Clearmind Medicine reports three published US patent applications - Mugglehead Investment Magazine
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations - Yahoo Finance
Three patent applications pair LSD, ketamine and ibogaine with a proprietary compound. - Stock Titan
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations - thenewswire.com
NeuroThera Labs Expands U.S. Patent Portfolio With LSD, Ketamine and Ibogaine Combinations via Clearmind Collaboration - kalkine.ca
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations - The Manila Times
Clearmind Medicine Announces U.S. Publication of Patent Applications Covering LSD, Ketamine and Ibogaine Combinations with N-Acylethanolamines - Quiver Quantitative
Clearmind testifies at FDA hearing on psychedelic therapies - Investing.com
Clearmind testifies at FDA hearing on psychedelic therapies By Investing.com - Investing.com Canada
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. - The Manila Times
About 1,800 people joined the FDA’s psychedelic hearing. Clearmind spoke on patient access. - Stock Titan
Why Did CMND Stock Jump 40% Today? - Stocktwits
Clearmind enrolls first AUD patients in CMND-100 trial - grafa.com
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial - The Manila Times
Clearmind enrolls first AUD patients in CMND-100 clinical trial By Investing.com - Investing.com UK
Two patients become the first to receive Clearmind's potential treatment for alcohol use disorder. - Stock Titan
Clearmind enrolls first AUD patients in CMND-100 clinical trial - Investing.com
Proposed Nasdaq threshold could threaten Clearmind (NASDAQ: CMND) listing - Stock Titan
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Charging Robotics Inc. Sells Majority Stake in Charging Israel to Clearmind Medicine for $2.5M (OTC: CHEV) - kalkinemedia.com
Clearmind gets Yale IRB approval for AUD trial enrollment By Investing.com - Investing.com India
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results - The Manila Times
All 24 trial participants completed treatment with no serious adverse events. Yale can now recruit. - stocktitan.net
Clearmind to acquire 51% stake in EV charging firm for $2.5M By Investing.com - Investing.com Australia
Clearmind Medicine to Acquire Majority Stake in Charging Robotics for $2.5 Million - marketscreener.com
CMND Stock Slides As Clearmind Medicine Tightens Cash Belt - StocksToTrade
Clearmind Tumbles on Buying into Charging Robotics - Baystreet.ca
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million - Yahoo Finance
Clearmind Medicine Stock Slides Friday: What's Happening? - Benzinga
CMND Stock Slides As Traders Eye Key Support Levels - timothysykes.com
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis - The Manila Times
Clearmind Medicine CMND-100 Advances As Psychedelic Pipeline Builds - StocksToTrade
Clearmind to acquire 51% stake in EV charging firm for $2.5M - Investing.com UK
Clearmind Medicine Inc. (CMND) moves into EV wireless charging with a controlling deal - Stock Titan
Clearmind Medicine ลงนามในข้อตกลงขั้นสุดท้ายเพื่อเข้าซื้อหุ้น 51% ในบริษัทระบบชาร์จไร้สายสำหรับระบบจอดรถอัตโนมัติและรถแท็กซี่ไร้คนขับ (Robotaxis) - Moomoo
Debt-for-share swap at $1 sets new floor at Clearmind (CMND) - Stock Titan
Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins - Blockonomi
Clearmind starts Phase IIa AUD trial of CMND-100 - Stock Titan
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled - The Manila Times
Clearmind Medicine Announces Initiation of Phase IIa Trial for CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine (CMND) Slips 2.76% to $1.76, Holds Above Key Support at $1.67ALMA Signal - careplusvn.com
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - The Manila Times
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - NewMediaWire
SciSparc: NeuroThera-Clearmind Collaboration Advances - GlobeNewswire
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionVolume Rate Change - vinanet.vn
Clearmind Medicine Company Profile & Introduction - Moomoo
Clearmind Medicine (CMND) Holds Near $1.86 as Biotech Stock Consolidates Within Key RangeFibonacci Extension - vinanet.vn
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial - Benzinga
Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder - Quiver Quantitative
Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc. (NASDAQ:CMND) - intelligentinvestor.com.au
Clearmind Medicine (CMND) holders report 9.99% cap on warrant-based stake - Stock Titan
Clearmind Medicine (CMND) reports intranasal MEAI permeation near 98% in study - Stock Titan
Clearmind Medicine Announces Positive Permeation Results For Intranasal Meai Formulation - TradingView
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery - The Manila Times
Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Program - Quiver Quantitative
3.06%
2.55%
자본화:
|
볼륨(24시간):